Chronic Obstructive Pulmonary Disease Market Size to Reach Around USD 24.3 Billion by 2026 : CAGR 4.9%

Pune, India -- (SBWire) -- 02/20/2019 --Global chronic obstructive pulmonary disease market size is anticipated to value around USD 24.3 billion by 2026. The market is foreseeable to display a CAGR of 4.9% during the coming years.

Free Download Sample Report Pages For Better understanding@ https://www.acumenresearchandconsulting.com/request-sample/1145

Various market players have gotten endorsements from the Food and Drug Administration (FDA), the European Commission, and other administrative experts in the previous couple of years. These players have propelled new products, for example, triple treatment drugs and different blends in the market, empowering them to increase noteworthy market share of the overall industry. In December 2018, AstraZeneca got endorsement from the European Commission (EC) for Bevespi Aerosphere in a pressurized metered-portion inhaler (pMDI) demonstrated as an upkeep double bronchodilator treatment in grown-up patients with COPD. This endorsement empowered the organization to add its innovatively propelled item to the current item offering for patients in Europe. In December 2018, Teva Pharmaceutical Industries Ltd. gotten the U.S. Sustenance and Drug Administration (FDA) endorsement for ProAir Digihaler inhaler powder, which is a digital inhaler with inherent sensors suggested to a sidekick versatile application. This endorsement helped the organization to fortify its development abilities in respiratory consideration, in this manner accomplishing huge development in the market.

The global chronic obstructive pulmonary disease treatment market is segmented into drug class, distribution channel and region. On the basis drug class, the global chronic obstructive pulmonary disease treatment market is segmented into Bronchodilators, Combination, Phosphodiesterase Type 4 Inhibitors, Mucokinetics, Corticosteroids, and Others. On the basis distribution channel, the global chronic obstructive pulmonary disease treatment market is segmented into Online Pharmacies, Hospital Pharmacies, and Retail Pharmacies. On the basis of region the global chronic obstructive pulmonary disease treatment market is bifurcated into North America, Latin America, Europe, Middle East & Africa, and Asia Pacific.

View Detail Information With Complete TOC@ https://www.acumenresearchandconsulting.com/chronic-obstructive-pulmonary-disease-treatment-market

Based on distribution channel, the market has been arranged into retail drug stores, emergency clinic drug stores, and online drug stores. The retail drug stores segment is required to grow at the quickest CAGR because of surge in the number of patients leaning toward retail drug stores. The online drug stores section is probably going to be driven by ascend in mindfulness about these drug stores among the overall public.

On the basis of drug class, the worldwide chronic obstructive pulmonary disease treatment market has been sectioned into bronchodilators, combination, phosphodiesterase type 4 inhibitors, corticosteroids, mucokinetics, and others. The combination segment has been segmented into long acting beta agonist & inhaled corticosteroids (LABA-ICS), triple therapy, long acting muscarinic antagonist & inhaled corticosteroids (LAMA-ICS), and others. The bronchodilators segment has been bifurcated into short acting beta agonist (SABA), long acting beta agonist (LABA), and long acting muscarinic rival (LAMA). The combination segment is anticipated to represent major share of the market by 2026 because of increment in number of doctors recommending combination treatment and increase in the number of medications accessible for COPD treatment. The bronchodilators segment is foreseen to develop at a steady pace attributable to increment in the appropriation of long acting muscarinic rival (LAMA) drugs.

Based on the region, the worldwide chronic obstructive pulmonary disease (COPD) treatment market has been classified into Europe, North America, Asia Pacific, Middle East and Africa, and Latin America. North America represented the biggest revenue share of the worldwide market in 2018. Presence of built up pharmaceutical organizations, increment in adoption of new drugs propelled in the market, and concentrate on dispatch of new products through R&D are foreseen to drive the market in the area amid the estimate time frame.

Click Here To Get Press Release: https://www.acumenresearchandconsulting.com/press-releases/chronic-obstructive-pulmonary-disease-treatment-market

The chronic obstructive pulmonary disease (COPD) treatment industry in Europe is driven by increment in R&D spending and introduction of new products. In November 2018, GlaxoSmithKline plc and Innoviva, Inc. gotten approval from the European Commission for extended use for once-daily TrelegyEllipta, first single inhaler triple treatment demonstrated for COPD patients who were not enough treated with dual bronchodilation.

Increase in commonness of COPD, high environmental contamination, increment in the geriatric populace, and development of the pharmaceutical business are foreseen to fuel the development of the chronic obstructive pulmonary disease (COPD) treatment market in Asia Pacific. An article published in the International Journal of Pulmonary and Respiratory Sciences expressed that COPD is the third driving reason for death in India.

The main business working in the global chronic obstructive pulmonary disease market are Orion Corporation, AstraZeneca, Mylan N.V., Boehringer Ingelheim Pharmaceuticals, Inc., Teva Pharmaceutical Industries Ltd., GlaxoSmithKline plc, Novartis AG, Sunovion Pharmaceuticals, Inc. and CHIESI Farmaceutici S.p.A.

Table Of Contents:

CHAPTER 1. INDUSTRY OVERVIEW

1.1. Definition and Scope
1.1.1. Definition of Chronic Obstructive Pulmonary Disease Treatment
1.1.2. Market Segmentation
1.1.3. List of Abbreviations
1.2. Summary
1.2.1. Market Snapshot
1.2.2. Chronic Obstructive Pulmonary Disease Treatment Market By Drug Class
1.2.2.1. Global Chronic Obstructive Pulmonary Disease Treatment Market Revenue and Growth Rate Comparison By Drug Class (2015-2026)
1.2.2.2. Global Chronic Obstructive Pulmonary Disease Treatment Market Revenue Share By Drug Class in 2017
1.2.2.3. Bronchodilators
1.2.2.4. Combination
1.2.2.5. Phosphodiesterase Type 4 Inhibitors
1.2.2.6. Mucokinetics
1.2.2.7. Corticosteroids
1.2.2.8. Others
1.2.3. Chronic Obstructive Pulmonary Disease Treatment Market By Distribution Channel
1.2.3.1. Global Chronic Obstructive Pulmonary Disease Treatment Market Revenue and Growth Rate Comparison By Distribution Channel (2015-2026)
1.2.3.2. Global Chronic Obstructive Pulmonary Disease Treatment Market Revenue Share By Distribution Channel in 2017
1.2.3.3. Online Pharmacies
1.2.3.4. Hospital Pharmacies
1.2.3.5. Retail Pharmacies
1.2.3.6. Others
1.2.4. Chronic Obstructive Pulmonary Disease Treatment Market by Geography
1.2.4.1. Global Chronic Obstructive Pulmonary Disease Treatment Market Revenue and Growth Rate Comparison by Geography (2015-2026)
1.2.4.2. North America Chronic Obstructive Pulmonary Disease Treatment Market Revenue and Growth Rate (2015-2026)
1.2.4.3. Europe Chronic Obstructive Pulmonary Disease Treatment Market Revenue and Growth Rate (2015-2026)
1.2.4.4. Asia-Pacific Chronic Obstructive Pulmonary Disease Treatment Market Revenue and Growth Rate (2015-2026)
1.2.4.5. Latin America Chronic Obstructive Pulmonary Disease Treatment Market Revenue and Growth Rate (2015-2026)
1.2.4.6. Middle East and Africa (MEA) Chronic Obstructive Pulmonary Disease Treatment Market Revenue and Growth Rate (2015-2026)

CHAPTER 2. MARKET DYNAMICS AND COMPETITION ANALYSIS

2.1. Market Drivers
2.2. Restraints and Challenges
2.3. Growth Opportunities
2.4. Porter's Five Forces Analysis
2.4.1. Bargaining Power of Suppliers
2.4.2. Bargaining Power of Buyers
2.4.3. Threat of Substitute
2.4.4. Threat of New Entrants
2.4.5. Degree of Competition
2.5. Value Chain Analysis
2.6. Cost Structure Analysis
2.6.1. Raw Material and Suppliers
2.6.2. Manufacturing Process Analysis
2.7. Regulatory Compliance
2.8. Competitive Landscape, 2017
2.8.1. Player Positioning Analysis
2.8.2. Key Strategies Adopted By Leading Players

CHAPTER 3. MANUFACTURING PLANTS ANALYSIS

3.1. Capacity and Commercial Production Date of Global Chronic Obstructive Pulmonary Disease Treatment Major Manufacturers in 2017
3.2. Manufacturing Plants Distribution of Global Chronic Obstructive Pulmonary Disease Treatment Major Manufacturers in 2017
3.3. R&D Status and Technology Source of Global Chronic Obstructive Pulmonary Disease Treatment Major Manufacturers in 2017
3.4. Raw Materials Sources Analysis of Global Chronic Obstructive Pulmonary Disease Treatment Major Manufacturers in 2017

CHAPTER 4. CHRONIC OBSTRUCTIVE PULMONARY DISEASE TREATMENT MARKET BY DRUG CLASS

4.1. Global Chronic Obstructive Pulmonary Disease Treatment Revenue By Drug Class
4.2. Bronchodilators
4.2.1. Market Revenue and Growth Rate, 2015 - 2026 ($Million)
4.2.2. Market Revenue and Forecast, By Region, 2015 - 2026 ($Million)
4.3. Combination
4.3.1. Market Revenue and Growth Rate, 2015 - 2026 ($Million)
4.3.2. Market Revenue and Forecast, By Region, 2015 - 2026 ($Million)
4.4. Phosphodiesterase Type 4 Inhibitors
4.4.1. Market Revenue and Growth Rate, 2015 - 2026 ($Million)
4.4.2. Market Revenue and Forecast, By Region, 2015 - 2026 ($Million)
4.5. Mucokinetics
4.5.1. Market Revenue and Growth Rate, 2015 - 2026 ($Million)
4.5.2. Market Revenue and Forecast, By Region, 2015 - 2026 ($Million)
4.6. Corticosteroids
4.6.1. Market Revenue and Growth Rate, 2015 - 2026 ($Million)
4.6.2. Market Revenue and Forecast, By Region, 2015 - 2026 ($Million)
4.7. Others
4.7.1. Market Revenue and Growth Rate, 2015 - 2026 ($Million)
4.7.2. Market Revenue and Forecast, By Region, 2015 - 2026 ($Million)

CHAPTER 5. CHRONIC OBSTRUCTIVE PULMONARY DISEASE TREATMENT MARKET BY DISTRIBUTION CHANNEL

5.1. Global Chronic Obstructive Pulmonary Disease Treatment Revenue By Distribution Channel
5.2. Online Pharmacies
5.2.1. Market Revenue and Growth Rate, 2015 - 2026 ($Million)
5.2.2. Market Revenue and Forecast, By Region, 2015 - 2026 ($Million)
5.3. Hospital Pharmacies
5.3.1. Market Revenue and Growth Rate, 2015 - 2026 ($Million)
5.3.2. Market Revenue and Forecast, By Region, 2015 - 2026 ($Million)
5.4. Retail Pharmacies
5.4.1. Market Revenue and Growth Rate, 2015 - 2026 ($Million)
5.4.2. Market Revenue and Forecast, By Region, 2015 - 2026 ($Million)
5.5. Others
5.5.1. Market Revenue and Growth Rate, 2015 - 2026 ($Million)
5.5.2. Market Revenue and Forecast, By Region, 2015 - 2026 ($Million)

CHAPTER 6. NORTH AMERICA CHRONIC OBSTRUCTIVE PULMONARY DISEASE TREATMENT MARKET BY COUNTRY

6.1. North America Chronic Obstructive Pulmonary Disease Treatment Market Revenue and Growth Rate, 2015 - 2026 ($Million)
6.2. North America Chronic Obstructive Pulmonary Disease Treatment Market Revenue Share Comparison, 2015 & 2026 (%)
6.3. U.S.
6.3.1. U.S. Chronic Obstructive Pulmonary Disease Treatment Market Revenue and Forecast By Drug Class, 2015 - 2026 ($Million)
6.3.2. Market Revenue and Forecast By Distribution Channel, 2015 - 2026 ($Million)
6.4. Canada
6.4.1. Market Revenue and Forecast By Drug Class, 2015 - 2026 ($Million)
6.4.2. Market Revenue and Forecast By Distribution Channel, 2015 - 2026 ($Million)
6.5. Mexico
6.5.1. Market Revenue and Forecast By Drug Class, 2015 - 2026 ($Million)
6.5.2. Market Revenue and Forecast By Distribution Channel, 2015 - 2026 ($Million)

CHAPTER 7. EUROPE CHRONIC OBSTRUCTIVE PULMONARY DISEASE TREATMENT MARKET BY COUNTRY

7.1. Europe Chronic Obstructive Pulmonary Disease Treatment Market Revenue and Growth Rate, 2015 - 2026 ($Million)
7.2. Europe Chronic Obstructive Pulmonary Disease Treatment Market Revenue Share Comparison, 2015 & 2026 (%)
7.3. UK
7.3.1. Market Revenue and Forecast By Drug Class, 2015 - 2026 ($Million)
7.3.2. Market Revenue and Forecast By Distribution Channel, 2015 - 2026 ($Million)
7.4. Germany
7.4.1. Market Revenue and Forecast By Drug Class, 2015 - 2026 ($Million)
7.4.2. Market Revenue and Forecast By Distribution Channel, 2015 - 2026 ($Million)
7.5. France
7.5.1. Market Revenue and Forecast By Drug Class, 2015 - 2026 ($Million)
7.5.2. Market Revenue and Forecast By Distribution Channel, 2015 - 2026 ($Million)
7.6. Spain
7.6.1. Market Revenue and Forecast By Drug Class, 2015 - 2026 ($Million)
7.6.2. Market Revenue and Forecast By Distribution Channel, 2015 - 2026 ($Million)
7.7. Rest of Europe
7.7.1. Market Revenue and Forecast By Drug Class, 2015 - 2026 ($Million)
7.7.2. Market Revenue and Forecast By Distribution Channel, 2015 - 2026 ($Million)

CHAPTER 8. ASIA-PACIFIC CHRONIC OBSTRUCTIVE PULMONARY DISEASE TREATMENT MARKET BY COUNTRY

8.1. Asia-Pacific Chronic Obstructive Pulmonary Disease Treatment Market Revenue and Growth Rate, 2015 - 2026 ($Million)
8.2. Asia-Pacific Chronic Obstructive Pulmonary Disease Treatment Market Revenue Share Comparison, 2015 & 2026 (%)
8.3. China
8.3.1. Market Revenue and Forecast By Drug Class, 2015 - 2026 ($Million)
8.3.2. Market Revenue and Forecast By Distribution Channel, 2015 - 2026 ($Million)
8.4. Japan
8.4.1. Market Revenue and Forecast By Drug Class, 2015 - 2026 ($Million)
8.4.2. Market Revenue and Forecast By Distribution Channel, 2015 - 2026 ($Million)
8.5. India
8.5.1. Market Revenue and Forecast By Drug Class, 2015 - 2026 ($Million)
8.5.2. Market Revenue and Forecast By Distribution Channel, 2015 - 2026 ($Million)
8.6. Australia
8.6.1. Market Revenue and Forecast By Drug Class, 2015 - 2026 ($Million)
8.6.2. Market Revenue and Forecast By Distribution Channel, 2015 - 2026 ($Million)
8.7. South Korea
8.7.1. Market Revenue and Forecast By Drug Class, 2015 - 2026 ($Million)
8.7.2. Market Revenue and Forecast By Distribution Channel, 2015 - 2026 ($Million)
8.8. Rest of Asia-Pacific
8.8.1. Market Revenue and Forecast By Drug Class, 2015 - 2026 ($Million)
8.8.2. Market Revenue and Forecast By Distribution Channel, 2015 - 2026 ($Million)

CHAPTER 9. LATIN AMERICA CHRONIC OBSTRUCTIVE PULMONARY DISEASE TREATMENT MARKET BY COUNTRY

9.1. Latin America Chronic Obstructive Pulmonary Disease Treatment Market Revenue and Growth Rate, 2015 - 2026 ($Million)
9.2. Latin America Chronic Obstructive Pulmonary Disease Treatment Market Revenue Share Comparison, 2015 & 2026 (%)
9.3. Brazil
9.3.1. Market Revenue and Forecast By Drug Class, 2015 - 2026 ($Million)
9.3.2. Market Revenue and Forecast By Distribution Channel, 2015 - 2026 ($Million)
9.4. Argentina
9.4.1. Market Revenue and Forecast By Drug Class, 2015 - 2026 ($Million)
9.4.2. Market Revenue and Forecast By Distribution Channel, 2015 - 2026 ($Million)
9.5. Rest of Latin America
9.5.1. Market Revenue and Forecast By Drug Class, 2015 - 2026 ($Million)
9.5.2. Market Revenue and Forecast By Distribution Channel, 2015 - 2026 ($Million)

CHAPTER 10. MIDDLE EAST CHRONIC OBSTRUCTIVE PULMONARY DISEASE TREATMENT MARKET BY COUNTRY

10.1. Middle East Chronic Obstructive Pulmonary Disease Treatment Market Revenue and Growth Rate, 2015 - 2026 ($Million)
10.2. Middle East Chronic Obstructive Pulmonary Disease Treatment Market Revenue Share Comparison, 2015 & 2026 (%)
10.3. Saudi Arabia
10.3.1. Market Revenue and Forecast By Drug Class, 2015 - 2026 ($Million)
10.3.2. Market Revenue and Forecast By Distribution Channel, 2015 - 2026 ($Million)
10.4. UAE
10.4.1. Market Revenue and Forecast By Drug Class, 2015 - 2026 ($Million)
10.4.2. Market Revenue and Forecast By Distribution Channel, 2015 - 2026 ($Million)
10.5. Rest of Middle East
10.5.1. Market Revenue and Forecast By Drug Class, 2015 - 2026 ($Million)
10.5.2. Market Revenue and Forecast By Distribution Channel, 2015 - 2026 ($Million)

CHAPTER 11. AFRICA CHRONIC OBSTRUCTIVE PULMONARY DISEASE TREATMENT MARKET BY COUNTRY

11.1. Africa Chronic Obstructive Pulmonary Disease Treatment Market Revenue and Growth Rate, 2015 - 2026 ($Million)
11.2. Africa Chronic Obstructive Pulmonary Disease Treatment Market Revenue Share Comparison, 2015 & 2026 (%)
11.3. South Africa
11.3.1. Market Revenue and Forecast By Drug Class, 2015 - 2026 ($Million)
11.3.2. Market Revenue and Forecast By Distribution Channel, 2015 - 2026 ($Million)
11.4. Egypt
11.4.1. Market Revenue and Forecast By Drug Class, 2015 - 2026 ($Million)
11.4.2. Market Revenue and Forecast By Distribution Channel, 2015 - 2026 ($Million)
11.5. Rest of Africa
11.5.1. Market Revenue and Forecast By Drug Class, 2015 - 2026 ($Million)
11.5.2. Market Revenue and Forecast By Distribution Channel, 2015 - 2026 ($Million)

CHAPTER 12. COMPANY PROFILE

12.1. Orion Corporation
12.1.1. Company Snapshot
12.1.2. Overview
12.1.3. Financial Overview
12.1.4. Product Portfolio
12.1.5. Key Developments
12.1.6. Strategies
12.2. AstraZeneca
12.2.1. Company Snapshot
12.2.2. Overview
12.2.3. Financial Overview
12.2.4. Product Portfolio
12.2.5. Key Developments
12.2.6. Strategies
12.3. Mylan N.V.
12.3.1. Company Snapshot
12.3.2. Overview
12.3.3. Financial Overview
12.3.4. Product Portfolio
12.3.5. Key Developments
12.3.6. Strategies
12.4. BoehringerIngelheim Pharmaceuticals, Inc.
12.4.1. Company Snapshot
12.4.2. Overview
12.4.3. Financial Overview
12.4.4. Product Portfolio
12.4.5. Key Developments
12.4.6. Strategies
12.5. Teva Pharmaceutical Industries Ltd.
12.5.1. Company Snapshot
12.5.2. Overview
12.5.3. Financial Overview
12.5.4. Product Portfolio
12.5.5. Key Developments
12.5.6. Strategies
12.6. GlaxoSmithKline plc
12.6.1. Company Snapshot
12.6.2. Overview
12.6.3. Financial Overview
12.6.4. Product Portfolio
12.6.5. Key Developments
12.6.6. Strategies
12.7. Novartis AG
12.7.1. Company Snapshot
12.7.2. Overview
12.7.3. Financial Overview
12.7.4. Product Portfolio
12.7.5. Key Developments
12.7.6. Strategies
12.8. Sunovion Pharmaceuticals, Inc.
12.8.1. Company Snapshot
12.8.2. Overview
12.8.3. Financial Overview
12.8.4. Product Portfolio
12.8.5. Key Developments
12.8.6. Strategies
12.9. CHIESI Farmaceutici S.p.A.
12.9.1. Company Snapshot
12.9.2. Overview
12.9.3. Financial Overview
12.9.4. Product Portfolio
12.9.5. Key Developments
12.9.6. Strategies
12.10. Others
12.10.1. Company Snapshot
12.10.2. Overview
12.10.3. Financial Overview
12.10.4. Product Portfolio
12.10.5. Key Developments
12.10.6. Strategies

CHAPTER 13. RESEARCH APPROACH

13.1. Research Methodology
13.1.1. Initial Data Search
13.1.2. Secondary Research
13.1.3. Primary Research
13.2. Assumptions and Scope

INQUIRY BEFORE BUYING@ https://www.acumenresearchandconsulting.com/inquiry-before-buying/1145

The report is readily available and can be dispatched immediately after payment confirmation.

Buy this premium research report – https://www.acumenresearchandconsulting.com/buy-now/0/1145

Would like to place an order or any question, please feel free to contact at sales@acumenresearchandconsulting.com| +1 407 915 4157

About Acumen Research and Consulting
Acumen Research and Consulting (ARC) is a global provider of market intelligence and consulting services to information technology, investment, telecommunication, manufacturing, and consumer technology markets. ARC helps investment communities, IT professionals, and business executives to make fact based decisions on technology purchases and develop firm growth strategies to sustain market competition. With the team size of 100+ Analysts and collective industry experience of more than 200 years, Acumen Research and Consulting assures to deliver a combination of industry knowledge along with global and country level expertise.